Ellen J. Scherl
Expertise in
17
conditions

Dr. Ellen J. Scherl

Gastroenterology
Jill Roberts Center For Inflammatory Bowel Disease
1283 York Ave # 9, 
New York, NY 
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
Jill Roberts Center For Inflammatory Bowel Disease
1283 York Ave # 9, 
New York, NY 

Overview

Ellen Scherl is a Gastroenterologist practicing medicine in New York, New York.

Dr. Scherl is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Crohn's Disease, Ulcerative Colitis, Viral Gastroenteritis, Endoscopy, and Colonoscopy.

She is actively involved in clinical research, co-authoring 106 peer reviewed articles and participating in 13 clinical trials. Dr. Scherl is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital
Hospital For Special Surgery

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 22 Less Insurance Carriers -

Locations

Jill Roberts Center for Inflammatory Bowel Disease
1283 York Ave # 9, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative Colitis
A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative Colitis
Enrollment Status: Completed
Publish Date: January 03, 2025
Intervention Type: Drug, Dietary supplement
Study Drug: Fecal Microbiota Transplantation
Study Phase: Phase 2
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

106 Total Publications

Risk Factors for Pouch Neoplasia in Patients With Inflammatory Bowel Disease: A Case-Control Study.
Risk Factors for Pouch Neoplasia in Patients With Inflammatory Bowel Disease: A Case-Control Study.
Journal: Gastro hep advances
Published: January 29, 2026
Similar Doctors
Expertise in
18
conditions
Dr. David A. Katzka
Gastroenterology
Expertise in
18
conditions
Dr. David A. Katzka
Gastroenterology
Referral may be required

ColumbiaDoctors - Midtown

51 W 51st St Ste 360, 
New York, NY 
 (1.3 miles away)
646-661-2756
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Katzka is a Gastroenterologist practicing medicine in New York, New York. Dr. Katzka is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Esophagitis, Eosinophilic Esophagitis, Barrett Esophagus, Endoscopy, and Gastrectomy.

Expertise in
36
conditions
Dr. Thomas D. Schiano
Gastroenterology
Expertise in
36
conditions
Dr. Thomas D. Schiano
Gastroenterology
Referral may be required

Recanati Miller Transplantation Institute

5 E 98th St Fl 12, 
New York, NY 
 (2.1 miles away)
212-257-0031
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Schiano is a Gastroenterologist practicing medicine in New York, New York. Dr. Schiano is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Autoimmune Hepatitis, Liver Transplant, and Kidney Transplant. Dr. Schiano is currently accepting new patients.

Expertise in
22
conditions
Dr. Ira M. Jacobson
Gastroenterology
Expertise in
22
conditions
Dr. Ira M. Jacobson
Gastroenterology
Referral may be required

New York University

530 1st Ave, 
New York, NY 
 (1.7 miles away)
212-263-0474
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ira Jacobson is a Gastroenterologist practicing medicine in New York, New York. Dr. Jacobson is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis C, Primary Biliary Cholangitis, Liver Transplant, and Endoscopy.

Frequently Asked Questions about Dr. Ellen J. Scherl

How do I make an appointment with Dr. Ellen J. Scherl?

You can book an appointment with Dr. Ellen J. Scherl by calling their office at 347-719-4936. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ellen J. Scherl a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ellen J. Scherl is classified as an Elite expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ellen J. Scherl specialize in?

While Dr. Ellen J. Scherl is a Gastroenterology, they have specific expertise in Crohn's Disease, Ulcerative Colitis, and Viral Gastroenteritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Ellen J. Scherl participate in research or clinical trials?

Yes. Dr. Ellen J. Scherl has published 106 articles and abstracts on conditions like Crohn's Disease. You can view a list of Dr. Ellen J. Scherl's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ellen J. Scherl accept my insurance?

Dr. Ellen J. Scherl accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 347-719-4936 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scherl's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile